Cowen & Co. Remains a Buy on Nucana Plc (NCNA)

By Ryan Adsit

In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Nucana Plc (NCNAResearch Report). The company’s shares closed last Monday at $7.60.

According to, Peaker is ranked 0 out of 5 stars with an average return of -2.3% and a 38.2% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.

Currently, the analyst consensus on Nucana Plc is a Strong Buy with an average price target of $23.33.

See today’s analyst top recommended stocks >>

Based on Nucana Plc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $5.75 million. In comparison, last year the company had a GAAP net loss of $3.28 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NuCana Plc engages in the development of technology platform for the treatment of patients with cancer. Its Protide technology is consists of acelarin, NUC-3373, and NUC-7738. The company was founded by Hugh S. Griffith and Christopher B. Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.